EDElena Danilova

Elena Danilova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Danilova has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Geir Hetland

    Department of Immunology, Institute of Clinical Medicine University of Oslo Oslo Norway

    2 shared publications
  • Agathe Martin

    Laboratoire de Préparation Cellulaire et d'Analyses Transfusion Interrégionale CRS Epalinges Switzerland

    1 shared publication
  • Ari Hemminki

    Finnish Red Cross Blood Service Vantaa Finland

    1 shared publication
  • Aseel Alshamari

    Department of Clinical Immunology and Transfusion Medicine, Faculty of Medicine and Health Örebro University Örebro Sweden

    1 shared publication
  • Barbora Jacobsen

    Department of Immunology and Transfusion Medicine St. Olavs Hospital Trondheim Norway

    1 shared publication
  • Betina Sørensen

    Department of Clinical Immunology Aalborg University Hospital Aalborg Denmark

    1 shared publication

Latest Publications

  • Open Access

    Practices in platelet production: A Nordic perspective (2018–2022)

    by Aseel Alshamari, Tynngård Nahreen, Jarkko Ihalainen, Ari Hemminki, Ragna Landrö, Erna Knútsdóttir, Betina Sørensen, Elena Danilova, Barbora Jacobsen, Marja‐Kaisa Auvinen, et al.

    Background and Objectives: The Nordic region includes Denmark, Finland, Iceland, Norway and Sweden, with a population of >27.5 million. Blood services are managed differently in each country. Current data on platelet concentrate ( PC ) production methods and capacity are important for developing efficiency and cross‐border preparedness. Materials and Methods: Retrospective data for 2018–2022 were collected through an online survey sent to all blood centres producing platelets in the region. Questions focused on collection procedures (aphaeresis [ AP ] or whole blood [ WB ]‐derived pools), use of bacterial culture screening ( BCS ) or pathogen reduction ( PR ), shelf‐life, transfusion practices and quality control. Results: A total of 43 blood centres provided data (83% response), including complete national coverage for Sweden, Finland and Iceland. Between 2018 and 2022, 632,596 PCs were produced at participating centres. Annual PC production was stable over the period. Most PCs were WB pools (77%). Automated separation to produce interim platelet unit ( IPU ) pools was performed at 19 centres. PR and BCS were used in 17 and 23 centres, respectively. Shelf‐life ranged from 5 days (no safety measure) to 7 days ( PR or BCS ). The number of PCs transfused in the region declined by ~5% from 2018 to 2022. Conclusion: Platelet production methods, including safety measures to prevent bacterial contamination, varied widely in the Nordic region. Harmonization, including the use of PR or BCS with 7‐day storage, may contribute to resilient platelet supplies in the region.


  • Open Access

    A validation study of the in vitro performance of hypoxic red blood cells for transfusion across centers in Europe

    by Vanessa Agostini, Reinhard Henschler, Turid Helen Felli Lunde, Einar Klæboe Kristoffersen, Geir Hetland, Elena Danilova, Agathe Martin, Michel Prudent, Giuliano Grazzini, Lucia De Franceschi, et al.

    Background: Refrigerated storage of red cell concentrate ( RCC ) leads to metabolic, oxidative, and structural changes that impair functionality and viability. These changes can be attenuated by hypoxic storage. Objective: This study assessed the quality of leucocytes‐reduced ( LR ), O 2 / CO 2 reduced red blood cells ( RBC ) stored for 42 days after pre‐storage O 2 / CO 2 reduction with the Hemanext ONE System, to verify compliance with regional and blood center acceptance criteria across six sites. Study design and methods: Validation studies of the in vitro performance of the LR , O 2 / CO 2 reduced storage (Hemanext ONE ) System were planned and executed at blood production centers in Italy, Germany, Norway and Switzerland. The endpoint‐associated study acceptance criteria included total hematocrit >50%, total hemoglobin ≥40 g and hemolysis <0.8%. Results: In total, 133 whole blood units donated at six blood centers were evaluated after processing with the Hemanext ONE System and after 21 and 42 days of storage. At Day 1 post‐processing, total hemoglobin (mean ± SD ) was 52.4 g/unit ± 3.1 and total hematocrit percentage (mean ± SD ) was 60.6% ± 7.0 (range, 51.9%–81.0%). Hemolysis at Day 42 of storage: overall mean ± SD , 0.26% ± 0.14. Discussion: Hypoxic RBCs met regulatory quality criteria regardless of collection and processing modalities. These results indicate that processing of RBCs stored under hypoxic conditions satisfies acceptance criteria for transfusion into patients in six European regional blood centers.


  • Open Access

    An evaluation of diethylhexyl phthalate free top & bottom in‐line blood collection set with a new soft housing filter

    by Elena Danilova, Farshid Ezligini, Connie Stöckel, Masafumi Asakawa, Geir Hetland

    Background and Objectives: Di (2‐ethylhexyl) phthalate (DEHP) plasticizer must be removed from polyvinylchloride (PVC) medical devices due to toxicity. DEHP/PVC blood bags were shown to provide stable quality under blood component production and to create good storage conditions for red blood cells concentrate (RBC). It is important that substitution of the DEHP maintains the RBC quality during storage, which should be achieved with Di (isononyl) cyclohexane‐1,2‐dicarboxylate (DINCH), although substitution of the plasticizer has been challenging.Materials and Methods: A DEHP‐free Top & Bottom in‐line RBC set was validated in a tertiary hospital blood bank facility. Volunteer blood donors were randomly allocated for blood collection into DINCH/PVC or DEHP/PVC set. The groups were additionally divided according to additive solution/filter combination: PAGGS‐M + DINCH/PVC filter (only with DINCH/PVC set), and SAG‐M + DINCH/PVC filter and SAG‐M + DEHP/PVC filter (only with DEHP/PVC set). Processing and storage effects were assessed in all components.Results: RBC concentrates, platelet concentrates and plasma that was processed and stored in DEHP‐free set fulfilled European requirements for quality. The cells stored in PAGGS‐M after filtration through DEHP‐free PVC filter showed the same low haemolysis compared with conventional set at 49 days of storage. Platelets stored in DINCH/PVC bag provided a sufficient quality of platelets after 7 days of storage. Plasma maintained the coagulation factors during 12 months of storage.Conclusion: A new DINCH/PVC set allows production of blood components of satisfactory quality in DEHP‐free environment.